XML 22 R7.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES      
Net loss $ (342,801) $ (229,828) $ (95,042)
Adjustments to reconcile net loss to cash used in operating activities:      
Depreciation and amortization 3,632 1,567 1,202
Net amortization of premiums or discounts on marketable securities 2,270 1,294 (787)
Amortization of debt issuance costs 187 0 0
Amortization of deferred contract acquisition costs 26,697 16,029 8,864
Non-cash operating lease costs 10,990 11,911 0
Common stock charitable donation expense 13,290 0 0
Stock-based compensation, net of amounts capitalized 155,624 143,341 18,617
Deferred income taxes 1,335 (1,335) (394)
Other 1,828 710 322
Changes in operating assets and liabilities:      
Accounts receivable (32,516) (41,612) (27,117)
Deferred contract acquisition costs (57,924) (38,129) (19,671)
Prepaid expenses and other assets (31,366) (14,368) (5,926)
Accounts payable 6,143 (327) 1,511
Accrued expenses and other liabilities 61,132 15,837 8,604
Operating lease liabilities (10,866) (11,224) 0
Deferred revenue 87,285 64,077 40,983
Net cash used in operating activities (105,060) (82,057) (68,834)
CASH FLOWS FROM INVESTING ACTIVITIES      
Capitalization of internal-use software costs (5,342) (3,610) (975)
Purchases of marketable securities (663,595) (329,616) (65,978)
Sales of marketable securities 0 4,988 33,104
Maturities of marketable securities 271,942 152,419 71,144
Purchases of property and equipment (3,600) (1,040) (1,954)
Other 12 0 300
Net cash (used in) provided by investing activities (400,583) (176,859) 35,641
CASH FLOWS FROM FINANCING ACTIVITIES      
Proceeds from initial public offering, net of underwriting discounts and commissions 786,600 0 0
Proceeds from issuance of common stock upon exercise of vested options 51,737 12,376 4,467
Proceeds from issuance of common stock upon early exercise of unvested options, net of repurchases 18,972 4,678 8,965
Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs 0 259,815 0
Payments of deferred offering costs (3,125) (111) 0
Debt instrument initial conversion price per share 1,081,300 0 0
Payments for purchase of capped calls (90,970) 0 0
Net cash provided by financing activities 1,844,514 276,758 13,432
Effect of exchange rate changes on cash, cash equivalents, and restricted cash 5 (7) (85)
Net increase (decrease) in cash, cash equivalents, and restricted cash 1,338,876 17,835 (19,846)
Cash, cash equivalents, and restricted cash at beginning of period 37,806 19,971 39,817
Cash, cash equivalents, and restricted cash at end of period 1,376,682 37,806 19,971
Reconciliation of cash, cash equivalents, and restricted cash within the consolidated balance sheets to the amounts shown above:      
Cash and cash equivalents 1,375,932 36,789 18,954
Restricted cash included in other assets, current and non-current 750 1,017 1,017
Total cash, cash equivalents, and restricted cash 1,376,682 37,806 19,971
Cash paid for:      
Income taxes 2,168 960 436
Non-cash investing and financing activities:      
Stock-based compensation capitalized in internal-use software costs 2,625 547 69
Right-of-use assets obtained in exchange for new operating lease liabilities 813 0 0
Property and equipment included in accounts payable and accrued expenses and other liabilities 0 203 60
Issuance of common stock upon exercise of vested options included in prepaid expenses and other current assets 55 54 0
Vesting of early exercised stock options 10,235 7,030 3,927
Conversion of convertible founder stock for Series E redeemable convertible preferred stock 0 109,035 0
Unpaid deferred offering costs 0 36 0
Convertible senior notes issuance costs included in accrued expenses and other liabilities $ 786 $ 0 $ 0